Recent Company News

• 10:39 PM ET Nov 04, 2025
  

  Eisai reports Q2 net income attributable ¥10.2B vs FactSet ¥11.32B [3 est, ¥5.83-16.74B] (¥4395.0000, -138)

• 06:07 AM ET Oct 30, 2025
  

  BioArctic receives SEK117.2M (+68% y/y) royalty from sales of Leqembi (SEK 289.00, -7.00)

• 07:08 AM ET Oct 29, 2025
  

  Merck and Eisai announce Phase 3 LEAP-012 trial in unresectable, non-metastatic hepatocellular carcinoma did not achieve statistical significance for overall survival ($87.03, 0.00)

• 06:35 AM ET Oct 28, 2025
  

  Merck and Eisai announce WELIREG (belzutifan) plus LENVIMA (lenvatinib) met primary endpoint of Progression-Free Survival (PFS) in certain previously treated patients with Advanced Renal Cell Carcinoma ($88.00, 0.00)

• 07:40 PM ET Oct 26, 2025
  

  Eisai receives approval for LEQEMBI in Canada for treatment of early Alzheimer's disease (¥4509.0000, 0)

• 06:10 AM ET Oct 18, 2025
  

  Merck, Eisai present long-term follow-up data on KEYTRUDA plus LENVIMA at ESMO

• 03:16 AM ET Oct 14, 2025
  

  BioArctic announces first patient treated with Leqembi (lecanemab) in the Nordics (SEK 291.00, -0.60)

• 06:51 AM ET Oct 09, 2025
  

  Merck announces new research to be presented at the ESMO Congress 2025 ($86.40, 0.00)

• 01:05 AM ET Oct 02, 2025
  

  Newron Pharmaceuticals to present new analyses and updates on its clinical program evaluating evenamide at ECNP Congress 2025 (CHF 10.92, 0.00)

• 07:38 PM ET Sep 28, 2025
  

  Biogen, Eisai advise approval in China for lecanemab IV maintenance dosing for the treatment of early alzheimer's disease ($137.37, 0.00)